Northwest Biotherapeutics Inc
NWBO
Get informed when a big investor buys or sells
+ FollowMarket Cap$312.24M
Close$
$-0.14
175.7% downside
Current Fair Value
175.7% downsideOvervalued by 175.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $312.24 Million |
|---|---|
| Enterprise Value | $368.08 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.04 |
| Beta | -0.62 |
| Outstanding Shares | 1,642,439,000 |
Return
| Return on Equity | 114.44% |
|---|---|
| Return on Assets | -52.41% |
| Return on Invested Capital | -1972.11% |
Valuation & Multiples
| P/E Ratio | -6.46 |
|---|---|
| PEG | 17.06 |
| Price to Sales | - |
| Price to Book Ratio | -0.19 |
| Enterprise Value to Revenue | 169.39 |
| Enterprise Value to EBIT | -7.21 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | -1.62 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$509,748
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.03%▲ 0.01% |
|---|---|
| Total Invested | $83,294▲ 90.77% |
| Investors Holding | 6▲ 1.00% |
ESG Score
No data
About Northwest Biotherapeutics Inc
CEO: Linda Powers